Baboon endogenous retrovirus (ERV) envelope pseudotyped lentiviral vectors outperform human ERV lentivectors for transduction of T, B, NK and HSPCs
Previously, we confirmed that BaEV-LVs outperformed VSV-G-LVs for gene delivery or correction of human T cells, B cells, NK cells and HSPCs correlating with high expression of its receptors, ASCT-1 and ASCT-2 on these cells. Since HERV-W gp uses the same entry receptors, we compared transduction efficiencies for BaEV-LVs and HERV-W-LVs in hematopoietic cells. HERV-W LV transduction was efficient but inferior to BaEV-LV in TCR-stimulated T cells (40% versus 80%) and this low efficiency was even more pronounced in IL-7/IL-15 pre-stimulated T cells. BaEV-LVs were significantly superior over HERV-W-LVs for the transduction of B cells and NK cells. High HERV-W-LV mediated transduction levels were achieved for pre-stimulated hCD34+ cells, which remained though lower than for the BaEV-LVs. Additionally, BaEV-LVs reached over 80% of transduction in severe combined immunodeficiency (SCID) repopulating cells (SRC) in 6/6 engrafted NBSGW mice. HERV-W-LVs reached this transduction level in 1/5 mice, while 3/5 engrafted NBSGW mice reached significantly lower transduction levels (20-50%). For both vectors the transduction levels were equivalent in the lymphoid and myeloid lineages in all hematopoietic tissues, suggesting transduction of immature HSPCs. Summarizing, BaEV-LVs outperformed HERV-W-LVs for transduction of important gene therapy target cells such as NK, B, T cells and CD34+ HSPCs.
Authors
- Els Verhoeyen (ORCID: https://orcid.org/0000-0001-9224-5491)
- Anne Galy (ORCID: https://orcid.org/0000-0002-0153-4392)
- Rimas J. Orentas (ORCID: https://orcid.org/0000-0002-6310-3467)
- Gisèle Froment
- Séverine Perian (ORCID: https://orcid.org/0000-0003-0942-7302)
- Caroline da Costa
- Eva Teresa Pérez Castellano
- Chiara Martinello
- Antonio Valeri
Institutions
- Université Claude Bernard Lyon 1 (FR)
- École Normale Supérieure de Lyon (FR)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Université Côte d'Azur (FR)
- Research Institute Hospital 12 de Octubre (ES)
- Centre Hospitalier Sud Francilien (FR)
- Centre Méditerranéen de Médecine Moléculaire (FR)
- Lentigen Technology (United States) (US)
Publication Details
- Journal
- Gene Therapy
- Published
- 2026-01-19
- DOI
- https://doi.org/10.1038/s41434-025-00587-w
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission
- Institut National de la Santé et de la Recherche Médicale
- Centre National de la Recherche Scientifique
- Université Claude Bernard Lyon 1
- École Normale Supérieure de Lyon
- HORIZON EUROPE Framework Programme
- Instituto de Salud Carlos III